<h4>Background</h4>Failure to CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), is an emerging clinical problem. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.